Spyre Therapeutics, Inc. SYRE Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

AmphenolAPH

$4.58B+174%

eBayEBAY

$4.23B+1.9%

Angel Oak MortgageAOMR

$43.65M+0.4%

Equity Lifestyle PropertiesELS

$39.24M-17.4%

Wintrust FinancialWTFC

$543.72M-11.8%

LFT

Lument Finance TrustLFT

$21.25M-66.5%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s cash cash equivalents and short term investments?: Spyre Therapeutics, Inc. (SYRE) reported cash cash equivalents and short term investments of $741.5M in Q1 2026.